Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Etanercept].

A Sparsa1

  • 1Service de Dermatologie, Hôpital Universitaire Dupuytren, Limoges. agnes.sparsa@chu-limoges.fr

Annales De Dermatologie Et De Venereologie
|December 6, 2005
PubMed
Summary
This summary is machine-generated.

Etanercept is a biologic therapy targeting TNF alpha, approved for rheumatoid arthritis and other inflammatory conditions. While effective, long-term side effects and cost require further evaluation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of bosentan for digital ulcers related to systemic sclerosis: a real-life retrospective French study of 89 patients treated since specific approval.

Scandinavian journal of rheumatology·2014
Same author

[Assessment of tele-expertise among elderly subjects in retirement homes].

Annales de dermatologie et de venereologie·2013
Same author

Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.

The British journal of dermatology·2012
Same author

[Historic malignant tumour: 27 observations].

Annales de dermatologie et de venereologie·2012
Same author

[Photodynamic therapy for the treatment of extramammary Paget's disease].

Annales de dermatologie et de venereologie·2012
Same author

[Eczema craquele].

Annales de dermatologie et de venereologie·2011
Same journal

2024 guidelines (S3) for the therapeutic management of patients with genital herpes.

Annales de dermatologie et de venereologie·2026
Same journal

Topical JAK inhibitors in the lichen planus spectrum: a systematic review.

Annales de dermatologie et de venereologie·2026
Same journal

2024 recommendations for the therapeutic management of anogenital warts.

Annales de dermatologie et de venereologie·2026
Same journal

Successful use of thalidomide in treating metastatic Crohn's disease.

Annales de dermatologie et de venereologie·2026
Same journal

Multiple cutaneous juvenile xanthogranuloma: a monocentric study.

Annales de dermatologie et de venereologie·2026
Same journal

Cartilage-hair-hypoplasia associated with granulomatosis induced by rubella vaccine.

Annales de dermatologie et de venereologie·2026
See all related articles

Area of Science:

  • Biotechnology and immunology
  • Pharmacology of anti-TNF agents

Context:

  • Etanercept is a biologic therapy targeting Tumor Necrosis Factor alpha (TNF alpha).
  • It is approved for rheumatoid arthritis, ankylosing spondylitis, juvenile rheumatoid arthritis, and psoriatic arthritis.
  • It is also under consideration for treating psoriasis.

Purpose:

  • To review the therapeutic applications of Etanercept (Enbrel).
  • To compare Etanercept with other anti-TNF alpha therapies like infliximab and adalimumab.
  • To discuss the role of TNF alpha in inflammatory diseases and the future of biotherapy.

Summary:

  • Etanercept, a soluble TNF alpha receptor fusion protein, is approved in the US and Europe for various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, and juvenile rheumatoid arthritis.

Related Experiment Videos

  • It offers an alternative to other disease-modifying antirheumatic drugs (DMARDs) and is being considered for psoriasis treatment.
  • While short-term adverse events are documented, long-term side effects remain unknown, and the high cost of biotherapy necessitates careful consideration.

    • Impact:

    • Etanercept represents a significant advancement in treating inflammatory diseases by targeting TNF alpha.
    • The increasing use of biotherapy, particularly anti-TNF alpha agents, is anticipated.
    • Further research is needed to fully understand long-term safety profiles and cost-effectiveness.